TY - JOUR
T1 - Chemical array system, a platform to identify novel hepatitis b virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide
AU - Kaneko, Manabu
AU - Futamura, Yushi
AU - Tsukuda, Senko
AU - Kondoh, Yasumitsu
AU - Sekine, Tomomi
AU - Hirano, Hiroyuki
AU - Fukano, Kento
AU - Ohashi, Hirofumi
AU - Saso, Wakana
AU - Morishita, Ryo
AU - Matsunaga, Satoko
AU - Kawai, Fumihiro
AU - Ryo, Akihide
AU - Park, Sam Yong
AU - Suzuki, Ryosuke
AU - Aizaki, Hideki
AU - Ohtani, Naoko
AU - Sureau, Camille
AU - Wakita, Takaji
AU - Osada, Hiroyuki
AU - Watashi, Koichi
N1 - Funding Information:
Huh7.5.1 cells were kindly provided by Dr. Francis Chisari at The Scripps Research Institute. pSVLD3 plasmid, encoding the HDV genome, was a kind gift from Dr. John Taylor at Fox Chase Cancer Center. The expression plasmids for preparing HCV pseudoparticles were kindly provided by Dr. Francois-Loic Cosset at University of Lyon. This study was supported by grants-in-aid from the Ministry of Health, Labor, and Welfare, Japan, from the Ministry of Education, Cultures, Sports, Science, and Technology, Japan, and from the Japan Society for the Promotion of Science KAKENHI (JP17H04085, JP16KT0111, JP16K19145, JP26460565, and JP26102747), JST CREST program, the Program on the Innovative Development and the Application of New Drugs for Hepatitis B (17fk0310114j0001 and 17fk0310101j1001), Japanese Initiative for Progress of Research on Infectious Disease for global Epidemic (J-PRIDE) (17fm0208019j0001) from the Japan Agency for Medical Research and Development (AMED), Takeda Science Foundation, and The Pharmacological Research Foundation, Tokyo.
Publisher Copyright:
© The Author(s) 2018.
PY - 2018
Y1 - 2018
N2 - Current anti-hepatitis B virus (HBV) agents including interferons and nucleos(t)ide analogs efficiently suppress HBV infection. However, as it is difficult to eliminate HBV from chronically infected liver, alternative anti-HBV agents targeting a new molecule are urgently needed. In this study, we applied a chemical array to high throughput screening of small molecules that interacted with sodium taurocholate cotransporting polypeptide (NTCP), an entry receptor for HBV. From approximately 30,000 compounds, we identified 74 candidates for NTCP interactants, and five out of these were shown to inhibit HBV infection in cell culture. One of such compound, NPD8716, a coumarin derivative, interacted with NTCP and inhibited HBV infection without causing cytotoxicity. Consistent with its NTCP interaction capacity, this compound was shown to block viral attachment to host hepatocytes. NPD8716 also prevented the infection with hepatitis D virus, but not hepatitis C virus, in agreement with NPD8716 specifically inhibiting NTCP-mediated infection. Analysis of derivative compounds showed that the anti-HBV activity of compounds was apparently correlated with the affinity to NTCP and the capacity to impair NTCP-mediated bile acid uptake. These results are the first to show that the chemical array technology represents a powerful platform to identify novel viral entry inhibitors.
AB - Current anti-hepatitis B virus (HBV) agents including interferons and nucleos(t)ide analogs efficiently suppress HBV infection. However, as it is difficult to eliminate HBV from chronically infected liver, alternative anti-HBV agents targeting a new molecule are urgently needed. In this study, we applied a chemical array to high throughput screening of small molecules that interacted with sodium taurocholate cotransporting polypeptide (NTCP), an entry receptor for HBV. From approximately 30,000 compounds, we identified 74 candidates for NTCP interactants, and five out of these were shown to inhibit HBV infection in cell culture. One of such compound, NPD8716, a coumarin derivative, interacted with NTCP and inhibited HBV infection without causing cytotoxicity. Consistent with its NTCP interaction capacity, this compound was shown to block viral attachment to host hepatocytes. NPD8716 also prevented the infection with hepatitis D virus, but not hepatitis C virus, in agreement with NPD8716 specifically inhibiting NTCP-mediated infection. Analysis of derivative compounds showed that the anti-HBV activity of compounds was apparently correlated with the affinity to NTCP and the capacity to impair NTCP-mediated bile acid uptake. These results are the first to show that the chemical array technology represents a powerful platform to identify novel viral entry inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85060084298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060084298&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-20987-w
DO - 10.1038/s41598-018-20987-w
M3 - Article
C2 - 29426822
AN - SCOPUS:85060084298
SN - 2045-2322
VL - 8
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 2769
ER -